Stay updated on Onasemnogene for SMA: Intrathecal Clinical Trial
Sign up to get notified when there's something new on the Onasemnogene for SMA: Intrathecal Clinical Trial page.

Latest updates to the Onasemnogene for SMA: Intrathecal Clinical Trial page
- Check3 days agoChange DetectedThe banner about a lapse in government funding and potential delays in updates has been removed. This notice was a general site operation message rather than content about the study details; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check10 days agoNo Change Detected
- Check18 days agoChange DetectedThe STRONG study (NCT03381729) has been terminated early by the sponsor due to strategic objectives within the intrathecal SMA program. No further enrollment or dosing is planned.SummaryDifference0.4%

- Check46 days agoChange DetectedExpanded topic coverage (Spinal muscular atrophy) and updated software version to v3.2.0, replacing the specific term Proximal spinal muscular atrophy and previous v3.1.0.SummaryDifference2%

- Check53 days agoChange Detected- Updated version from v3.0.2 to v3.1.0. - No other content changes detected.SummaryDifference0.1%

- Check68 days agoChange DetectedThe page now shows Revision: v3.0.2 (replacing v3.0.1), indicating a new release. The Back to Top element was removed, which is a minor UI change.SummaryDifference0.1%

- Check75 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content, names, pricing, or availability.SummaryDifference0.1%

Stay in the know with updates to Onasemnogene for SMA: Intrathecal Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Onasemnogene for SMA: Intrathecal Clinical Trial page.